• UCB's FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug

    6 days ago - By MedCity News

    The FDA cited manufacturing issues in turning down UCB's application seeking approval for bimekizumab, an antibody drug developed to treat moderate-to-severe plaque psoriasis. Bimekizumab is already approved and available in other markets around world, but the FDA rejection delays UCB's antibody drug from competing in the U.S. for now.
    Read more ...